Acupuncture for cancer pain: an evidence-based clinical practice guideline

This study represents an important milestone in integrative oncology by establishing the first evidence-based clinical guidelines for the use of acupuncture in the treatment of cancer pain. Developed by the International Working Group for Trustworthy Traditional Chinese Medicine Recommendations (TCM Recs), the document was prepared by a multidisciplinary international panel of 13 oncologists, traditional Chinese medicine and acupuncture practitioners, methodology experts, and two patient representatives. The methodology rigorously followed World Health Organization standards for guideline development, using the GRADE approach to assess the certainty of evidence and the strength of recommendations. The development was based mainly on a high-quality systematic review published in JAMA Oncology in 2020, which analyzed studies through March 2019, covering 2,505 patients with cancer pain.

The three main recommendations establish that: first, there is a strong recommendation for the use of acupuncture versus no treatment for pain relief in patients with moderate to severe cancer pain, based on moderate-certainty evidence. This recommendation is supported by eight randomized clinical trials involving 530 patients, showing a significant reduction in pain intensity both compared with sham acupuncture (1.39-point reduction on the numeric rating scale) and with waiting list (1.63-point reduction). Second, there is a weak recommendation for combined acupuncture/acupressure treatments to reduce pain intensity, decrease opioid dose, and alleviate opioid-related side effects in patients already using analgesics, based on low-certainty evidence. Third, there is a strong recommendation for acupuncture in patients with breast cancer for relief of aromatase inhibitor-induced arthralgia, supported by low-certainty evidence but with significant clinical benefits.

The guideline identifies that there is no significant difference between different acupuncture techniques (manual, electroacupuncture, and auricular), allowing flexibility in the choice of modality. The main recommended acupuncture points include Hegu (LI-4), Taichong (LR-3), Ashi points, Zusanli (ST-36), Sanyinjiao (SP-6), and Yanglingquan (GB-34), with personalized selection based on the patient's specific condition. In terms of safety, the analysis did not identify serious adverse events related to treatment, with only mild effects such as pain at the puncture site, hematoma, or minimal bleeding reported in about 8% of patients. The document also examined patient preferences and values through eight cross-sectional studies involving 2,505 American and Swedish patients, revealing that 79-97% of patients with cancer consider acupuncture valuable, important, or effective, and about one-third (27-42%) prefer acupuncture to medications for pain control.

The cost analysis demonstrates that acupuncture is cost-effective, with median values of $112 for the first consultation and $80 for subsequent consultations in the US. Access to acupuncture has improved globally, with more than 34,000 licensed acupuncturists in the US alone and growing health insurance coverage. The clinical implications are substantial, offering oncologists and patients an evidence-based alternative or complement for cancer pain management, particularly relevant in the context of the opioid crisis. The guideline establishes specific treatment protocols, including frequency (twice a week), duration (30 minutes per session), and course (6 weeks for manual acupuncture), providing practical guidance for clinical implementation.